United States newsroom

Myrbetriq is the first and only beta-3 adrenergic agonist indicated for the treatment of overactive bladder NORTHBROOK, Ill., June 28, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a...

Event Kicks Off Astellas' Annual Changing Tomorrow Day Volunteer Initiative KISSIMMEE, Fla., June 13, 2012 /PRNewswire/ -- Give Kids The World Village (GKTW) will host its largest single...

Japanese Pharmaceutical Company Expands in Glenview GLENVIEW, Ill. – June 4, 2012. Governor Pat Quinn today joined Astellas executives and more than 1,000 employees to open the company’s new...

Dose-Escalation Completed and Preliminary Antitumor Activity Observed Santa Monica, CA and Bothell, WA – June 4, 2012 – Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and...

On May 21, 2012, the American Urological Association (AUA) issued the first guidelines specific to the diagnosis and treatment of overactive bladder (OAB) in the U.S. Astellas supports these new...

DEERFIELD, Ill., April 5, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the Reproductive...

DEERFIELD, Ill., Feb. 21, 2012 /PRNewswire/ -- Astellas announces Charlotte M. E. Kremer, MD, MBA has joined the company as the head of one of the Company's newest organizations – Global Medical...

CARMEL, Calif. and DEERFIELD, Ill., Feb. 7, 2012 /PRNewswire/ -- Today, Science Buddies and Astellas USA Foundation ("Foundation") announced initiation of the Science Buddies-Astellas Rosalind...

SAN DIEGO, Calif. and Deerfield, Ill., December 21, 2011 — Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...

Frank P. Hudson as Vice President of Finance Wolfgang Noe, Ph.D., as Vice President, Process Sciences and Manufacturing SANTA MONICA, Calif., Dec. 1, 2011 /PRNewswire/ -- Agensys, Inc....

More than 500 Astellas Employees Tackle Improvement Projects as Part of Company's Commitment to Service DEERFIELD, Ill., Sept. 23, 2011 /PRNewswire/ -- More than 500 employees from Astellas Pharma...

DEERFIELD, IL, September 15, 2010 – On January 1, 2011, the Donate Life float will roll through the streets of Pasadena reminding millions of viewers of the Rose Parade® to “Seize the Day”...

DEERFIELD, Ill., Aug. 15, 2011 /PRNewswire/ -- Astellas US, LLC ("Astellas") recently named Percival Barretto-Ko as Senior Vice President, Corporate Strategy and Government Affairs, a new position...

WHITEHOUSE STATION, N.J. and DEERFIELD, Ill., July 26, 2011 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Astellas US LLC ("Astellas"), the U.S. subsidiary of...

DEERFIELD, Ill., June 6, 2011 /PRNewswire/ -- Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, today announced that it will be presenting data...

SOUTH SAN FRANCISCO, Calif. – June 2, 2011 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Astellas Pharma US, Inc. (“Astellas”), today announced results of...

DEERFIELD, Ill., May 19, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") recently hired Mark Reisenauer as vice president of sales and marketing, oncology. Reporting directly to Patrick...

DEERFIELD, Ill., May 17, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas Pharma US"), U.S. subsidiary of Astellas Pharma Inc. (Tokyo: TSE: 4503, "the Company"), today announced the...

DEERFIELD, Ill., May 3, 2011 /PRNewswire/ -- Astellas Pharma Global Development, Inc. ("APGD"), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, welcomes four seasoned industry leaders...

EURTAC is the First Phase III Study to Show Progression-Free Survival Benefit of First-Line Tarceva in a Western Population with Advanced Lung Cancer With EGFR Mutations SOUTH SAN FRANCISCO,...

Tokyo, – January 10, 2011 – Astellas Pharma Inc. (TSE: 4503) announced today that it has engaged Citigroup Global Markets Inc. to conduct, in conjunction with executive management, a review of...

48 Middle and Secondary School Science Teachers From Across the Country to Begin Year-long Professional Development Journey ARLINGTON, Va. — November 15, 2010 — The National Science Teachers...

TOKYO, Nov. 2, 2010 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that Donald B. Rice, PhD. will retire from Astellas...

CHICAGO and DEERFIELD, Ill., Nov. 2, 2010 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a research-based pharmaceutical company based in Deerfield, Ill., is pleased to donate 150 used...

K-12 Science Teachers and Parents Also Agree Outside Mentors and Use of Technology Resources Can Play an Important Role CHICAGO AND DEERFIELD, IL, October 28, 2010 – A new national survey...

Phase IV Data Meets Primary Endpoint PHILADELPHIA, PA, September 25, 2010 – Today Astellas Pharma US, Inc., (“Astellas”) announced results of a Phase IV study showing Lexiscan®...

PHILADELPHIA, PA, September 24, 2010 - Today Astellas Pharma US, Inc. ("Astellas") announced the Launch of the Appropriate Use Criteria (AUC) for Cardiac Radionuclide Imaging application (app) for...

DEERFIELD, IL, September 15, 2010 – Astellas Pharma US, Inc. has announced the winners of the second 2010 Transplant Scholars Awards, which awarded a dozen $5,000 educational scholarships to...

SANTA MONICA, Calif.- Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate...

Astellas Launches Science WoRx Program Aimed to Ignite Students' Passion for Science and Cultivate the Next Generation of Scientists Today Astellas Pharma US, Inc. ("Astellas") announced the...

Company Breaks Ground in Glenview, Will Create 150 Jobs GLENVIEW, IL – April 29, 2010. Governor Pat Quinn today announced an approximately $4 million investment package to assist Astellas Pharma...

MELVILLE, N.Y., Apr 29, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the...

MELVILLE, N.Y., Apr 26, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing...

First Maintenance Therapy Approved For a Broad Patient Population Including Squamous and Non- Squamous Histology MELVILLE, N.Y., Apr 16, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ:...

Survey Reveals Pervasive Donation Myths RICHMOND, Va. (April 5, 2010) – According to a new survey by Donate Life America, 43 percent of people are undecided, reluctant or do not wish to have...

MELVILLE, N.Y., Mar 19, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva(R) (erlotinib), Roche, informed OSI that the...

MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif., Jan 15, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG;...

Innovative Needle-Free Delivery System Provides Fast Migraine Relief SAN DIEGO, Calif. and DEERFIELD, Ill., January 13, 2010 — Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical...

Fourth Quarter U.S. Tarceva Sales Increased 17% on Prior Year to $137 Million Total Global Tarceva Sales for 2009 Top $1.2 Billion MELVILLE, N.Y., Jan 12, 2010 (BUSINESS WIRE) -- OSI...

MELVILLE, N.Y., Dec 29, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065,...

GAITHERSBURG, Md., Dec 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG)(OTCQX: RHHBY), announced...

MOTTEP Honors Astellas for Commitment to Transplant Community Deerfield, IL (December 7, 2009) – Astellas Pharma US, Inc. was inducted into the National Minority Organ Tissue Transplant...

MELVILLE, N.Y., Nov 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Oncologic Drugs Advisory Committee (ODAC) will review the use of Tarceva(R)...

SOUTH SAN FRANCISCO, CA and DEERFIELD, IL – November 5, 2009 – Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in...

Vancouver, Canada and Deerfield, Illinois, USA, October 28, 2009 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”)...

Challenge to state of Illinois: 5,000 new organ donor registrations by the end of the year Deerfield, IL (October 26, 2009) – On November 1, 1999 Chicago Bears fans and the organ donation...

Data Published in Headache Highlights Bioequivalence, Safety and Ease of Use SAN DIEGO, CA and Deerfield, IL - (October 22, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical...

Study finds aminophylline needs comparable to current standard Minneapolis – October 2, 2009 – A new analysis reaffirms that Lexiscan® (regadenoson) Injection, the first selective A2A...

DEERFIELD, IL, September 22, 2009 – Astellas Pharma US, Inc. has announced the winners of the first annual Astellas Transplant Scholars Awards, $5,000 educational scholarships awarded to six...

Astellas provides ongoing support for greater Chicago-area science teachers to advance their career skills DEERFIELD, IL, September 21, 2009 – Astellas Pharma US, Inc. (“Astellas”), in...